Search
Gonadorelin
go.drugbank.com/drugs/DB00644ApprovedInvestigationalVet approvedIt is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Mixtures: Relisorm 100 for Inj.-pws Liq-kit Sc IVProducts: LH-RH FERRING 0,1 MG/ML IV ENJEKSIYONLUK COZELTI ICEREN AMPUL, 1 ADET, Kryptocur 0,2 mg/0,1 ml - nasale SprühlösungLynestrenol
go.drugbank.com/drugs/DB12474ApprovedWithdrawnLynestrenol is a progestin and prodrug of [norethisterone].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ORGAMETRİL 5 MG TABLET, 30 ADETEthambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967. … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.
Synonyms: (+)-2,2'-(ethylenediimino)di-1-butanol, (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamineMixtures: RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MG, RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MGAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: SUNVEPRA 100 MG KAPSÜL, 56 ADET, SUNVEPRA® 100MG CÁPSULAS BLANDASEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesProducts: REVOLADE ® TABLETAS 50 MG, ROMPAG 50 MG FİLM KAPLI TABLET, 14 ADETLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Categories: MATE 1 Inhibitors, Heterocyclic Compounds, 1-RingProducts: LORBRENA® 100 MG, LORVIQUA (TABLETS 100 MG)Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigational[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. … In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein substratesSynonyms: 2-chloro-N-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-Bismuth subsalicylate
go.drugbank.com/drugs/DB01294ApprovedVet approved[A230733] Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection. … [A230728] It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract.
Synonyms: 2-Hydroxy-benzo[1,3,2]dioxabismin-4-oneProducts: BİZMOPEPTOL 525 MG/30 ML ORAL SÜSPANSİYON , 240 ML, BİZMOPEPTOL 525 MG/30 ML ORAL SÜSPANSİYON , 480 MLDolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalDolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. … This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Categories: Serotonin 5-HT3 Receptor Antagonists, Antiemetic Serotonin 5-HT3 Receptor AntagonistsProducts: Anzemet Injection 20 mg/mlPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.
Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLE